Skip to main content

Table 1 Clinical characteristics of the normal control and diabetic patients before and after 3 months of telmisartan treatment

From: Telmisartan improves cardiac fibrosis in diabetes through peroxisome proliferator activated receptor δ (PPARδ): from bedside to bench

  Normal control (n = 10) Baseline (n = 15) After telmisartan (n = 15) p value
Age (years) 52.2 ± 8.5 55.3 ± 8.8 0.25
Male (%) 6 (60) 11 (73.3) 0.12
Body height (cm) 165.8 ± 7.4 163.9 ± 8.7 0.72
Body weight (kg) 68.6 ± 7.1 70.8 ± 10.6 0.81
Heart rate (beats/min) 69.8 ± 7.6 73.5 ± 8.24 72.38 ± 11.74 0.64
Systolic blood pressure (mmHg) 120.2 ± 12.9 129.6 ± 17.1 122.1 ± 14.4 0.06
Diastolic blood pressure (mmHg) 83 ± 8.9 82.6 ± 7.7 85.2 ± 13.9 0.43
Preprandial serum glucose (mg/dL) 92.7 ± 5.6 122 ± 15.8 105.3 ± 10.6 0.01
HbA1c (%) 5.6 ± 0.9 7.8 ± 1.2 7.2 ± 0.8 0.02
Creatinine clearance rate (ml/min) 108.7 ± 45.8 83.7 ± 24.5 95.8 ± 24.6 0.29
Triglyceride (mg/dL) 122.6 ± 51.3 129 ± 6.2 0.59
Cholesterol (mg/dl) 178.7 ± 28.8 178.6 ± 32.3 0.67
  1. Data are expressed as mean ± standard deviation or median (interquartile range). Italic values indicate significance
  2. HbA1c hemoglobin A1c